Rodríguez-Gascón A - Search Results

1

Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs.

Beloqui A, Solinís MÁ, des Rieux A, Préat V, Rodríguez-Gascón A. Beloqui A, et al. Int J Pharm. 2014 Jul 1;468(1-2):105-11. doi: 10.1016/j.ijpharm.2014.04.027. Epub 2014 Apr 16. Int J Pharm. 2014. PMID: 24746410

2

In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations.

Cuadrado A, Rodríguez Gascón A, Hernández RM, Castilla AM, de la Maza A, Yánez C, López de Ocáriz A, Solinís MA, Pedraz JL. Cuadrado A, et al. Arzneimittelforschung. 2003;53(5):321-9. doi: 10.1055/s-0031-1297116. Arzneimittelforschung. 2003. PMID: 12854359 Clinical Trial.

3

[Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology].

Isla A, Canut A, Rodríguez-Gascón A, Labora A, Ardanza-Trevijano B, Solinís MA, Pedraz JL. Isla A, et al. Enferm Infecc Microbiol Clin. 2005 Mar;23(3):116-21. doi: 10.1157/13072159. Enferm Infecc Microbiol Clin. 2005. PMID: 15757581 Review. Spanish.

4

Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.

Isla A, Rodríguez-Gascón A, Trocóniz IF, Bueno L, Solinís MA, Maynar J, Sánchez-Izquierdo JA, Pedraz JL. Isla A, et al. Clin Pharmacokinet. 2008;47(3):173-80. doi: 10.2165/00003088-200847030-00003. Clin Pharmacokinet. 2008. PMID: 18307371 Clinical Trial.

5

Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway.

Delgado D, del Pozo-Rodríguez A, Solinís MÁ, Rodríguez-Gascón A. Delgado D, et al. Eur J Pharm Biopharm. 2011 Nov;79(3):495-502. doi: 10.1016/j.ejpb.2011.06.005. Epub 2011 Jun 25. Eur J Pharm Biopharm. 2011. PMID: 21726641

6

Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.

Isla A, Trocóniz IF, de Tejada IL, Vázquez S, Canut A, López JM, Solinís MÁ, Rodríguez Gascón A. Isla A, et al. Eur J Clin Pharmacol. 2012 May;68(5):735-45. doi: 10.1007/s00228-011-1206-1. Epub 2012 Jan 15. Eur J Clin Pharmacol. 2012. PMID: 22246211

7

Biodistribution of Nanostructured Lipid Carriers (NLCs) after intravenous administration to rats: influence of technological factors.

Beloqui A, Solinís MA, Delgado A, Evora C, del Pozo-Rodríguez A, Rodríguez-Gascón A. Beloqui A, et al. Eur J Pharm Biopharm. 2013 Jun;84(2):309-14. doi: 10.1016/j.ejpb.2013.01.029. Epub 2013 Feb 24. Eur J Pharm Biopharm. 2013. PMID: 23461861

8

Gene therapy for fabry disease: a review of the literature.

Ruiz de Garibay AP, Solinís MA, Rodríguez-Gascón A. Ruiz de Garibay AP, et al. BioDrugs. 2013 Jun;27(3):237-46. doi: 10.1007/s40259-013-0032-7. BioDrugs. 2013. PMID: 23575647 Review.

9

Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution.

Beloqui A, Solinís MÁ, Delgado A, Evora C, Isla A, Rodríguez-Gascón A. Beloqui A, et al. J Microencapsul. 2014;31(1):1-8. doi: 10.3109/02652048.2013.788090. Epub 2013 Apr 30. J Microencapsul. 2014. PMID: 23631381

10

Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.

Beloqui A, Coco R, Alhouayek M, Solinís MÁ, Rodríguez-Gascón A, Muccioli GG, Préat V. Beloqui A, et al. Int J Pharm. 2013 Oct 1;454(2):775-83. doi: 10.1016/j.ijpharm.2013.05.017. Epub 2013 May 18. Int J Pharm. 2013. PMID: 23694806

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters